Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines

Masahiro Yoshida*, Tadahiro Takada, Yoshifumi Kawarada, Atsushi Tanaka, Yuji Nimura, Harumi Gomi, Masahiko Hirota, Fumihiko Miura, Keita Wada, Toshihiko Mayumi, Joseph S. Solomkin, Steven Strasberg, Henry A. Pitt, Jacques Belghiti, Eduardo de Santibanes, Sheung Tat Fan, Miin Fu Chen, Giulio Belli, Serafin C. Hilvano, Sun Whe KimChen Guo Ker

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

66 引文 斯高帕斯(Scopus)

摘要

Acute cholecystitis consists of various morbid conditions, ranging from mild cases that are relieved by the oral administration of antimicrobial drugs or that resolve even without antimicrobials to severe cases complicated by biliary peritonitis. Microbial cultures should be performed by collecting bile at all available opportunities to identify both aerobic and anaerobic organisms. Empirically selected antimicrobials should be administered. Antimicrobial activity against potential causative organisms, the severity of the cholecystitis, the patient's past history of antimicrobial therapy, and local susceptibility patterns (antibiogram) must be taken into consideration in the choice of antimicrobial drugs. In mild cases which closely mimic biliary colic, the administration of nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended to prevent the progression of inflammation (recommendation grade A). When causative organisms are identified, the antimicrobial drug should be changed for a narrower-spectrum antimicrobial agent on the basis of the species and their susceptibility testing results.

原文英語
頁(從 - 到)83-90
頁數8
期刊Journal of Hepato-Biliary-Pancreatic Sciences
14
發行號1
DOIs
出版狀態已出版 - 01 2007
對外發佈

指紋

深入研究「Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines」主題。共同形成了獨特的指紋。

引用此